ReviewCancer immunology, immunotherapy : CII2007
Immune selective pressure and HLA class I antigen defects in malignant lesions.
Review in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Global research trends and focus on immunotherapy for endometrial cancer: a comprehensive bibliometric insight and visualization analysis (2012-2024).Frontiers in immunology · 2025Pooled it
- Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.Frontiers in immunology · 2021Trial
- Race, ethnicity, ancestry, and aspects that impact HLA data and matching for transplant.Frontiers in genetics · 2024Article
- Differential HLA class I subunit (A, B, C heavy chain and βVirchows Archiv : an international journal of pathology · 2023Article
- Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.JAMA oncology · 2022Review
- Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.Frontiers in oncology · 2022Review
- NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.Transplantation and cellular therapy · 2021Review
- Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer.Clinical and experimental medicine · 2020Article
- Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.Neoplasia (New York, N.Y.) · 2018Article
- Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.Journal of translational medicine · 2017Article
- Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.Scientific reports · 2017Article
- Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.The Journal of experimental medicine · 2016Article
- Immunotherapy as a Potential Treatment for Chordoma: a Review.Current oncology reports · 2016Review
- Mutanome and expression of immune response genes in microsatellite stable colon cancer.Oncotarget · 2016Article
- Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Frontiers in pharmacology · 2016Review
- Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance.Cancer immunology, immunotherapy : CII · 2016Article
- Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.The Journal of biological chemistry · 2015Article
- Differences in genetic variation in antigen-processing machinery components and association with cervical carcinoma risk in two Indonesian populations.Immunogenetics · 2015Article
- Tumor cell secretion of soluble factor(s) for specific immunosuppression.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The revived cancer immune surveillance theory has emphasized the active role the immune system plays in eliminating tumor cells and in facilitating the emergence of their immunoresistant variants. MHC class I molecule abnormalities represent, at least in part, the molecular phenotype of these escape variants, given the crucial role of MHC class I molecules in eliciting tumor antigen-specific T cell responses, the high frequency of HLA class I antigen abnormalities in malignant lesions and their association with a poor clinical course of the disease. Here, we present evidence for this possibility and review the potential mechanisms by which T cell selective pressure participates in the generation of tumor cells with MHC class I molecule defects. Furthermore, we discuss the strategies to counteract tumor cell immune evasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.